• Revance Botulinum Toxin Achieves Six-Month Duration in Phase 3 Trials

    6 days ago - By Surgical Aesthetics Magazine

    Revance Therapeutics' DaxibotulinumtoxinA for Injection achieved six-month duration in two pivotal SAKURA Phase 3 clinical studies for the treatment of glabellar lines. RT002 met its primary composite endpoint by delivering highly statistically significant improvement against placebo in reducing the severity of glabellar lines in both SAKURA 1 and SAKURA 2.
    In SAKURA 1, 73.6 percent of RT002-treated patients achieved at least a two-point improvement from baseline on both validated physician and patient assessments at week four. In SAKURA 2, it was 74 percent. At that time point, 88 percent...
    Read more ...

     

  • National Clinical Trial Finds Certain Treatments for Blood Clots Not Effective

    National Clinical Trial Finds Certain Treatments for Blood Clots Not Effective

    7 days ago - By UNC Healthcare

    Stephan Moll, MD, professor of medicine and member of the UNC Hemophilia and Thrombosis Center, co-authored the results of a large-scale multicenter clinical trial focusing on catheter-directed thrombolysis and its effects.
    Read more ...